Concepedia

Wei Yu

WY

Statistics

Publications

7

Citations

1.3K

H-Index

7

Active since

2012

Affiliations

Sarah Cannon(Current)

Hospital Universitario Virgen del Rocío

Tennessee Oncology

University of Maryland, Baltimore

Chinese University of Hong Kong

Wei Yu is an author at Sarah Cannon specializing in medicine, oncology, and non-small cell lung cancer therapy.

Publications per year

2012–2020

7

Publications

7

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2013 · 477 citations · Full text

, , +17

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne et al. · Journal of Clinical Oncology · 2017 · 326 citations

, , +13

Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne et al. · Journal of Clinical Oncology · 2014 · 147 citations

, , +14

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha et al. · Clinical Cancer Research · 2014 · 133 citations · Full text

, , +17

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

David R. Spigel, Martin J. Edelman, Tony Mok et al. · Clinical Lung Cancer · 2012 · 90 citations

, , +17

1–5 of 7